NPPB and hydrops fetalis: PROVE HF (prospective investigation of ventricular remodeling, symptom relief, and biomarkers throughout Entresto therapy for HF) and EVALUATE HF (study comparing the effects of sacubitril/valsartan and enalapril on aortic stiffness in individuals with mild to moderate HF and a low ejection fraction) showed that ARNI-treated patients experienced positive LV remodeling, which was accompanied by a drop in NT-proBNP levels and clinical improvement; however, LVNC patients were not included in these investigations [66,67].